Published: 2017-06-23

Effect of amlodipine on blood glucose level in euglycemic and streptozotocin induced diabetic Albino rats and its pharmacodynamic interaction with glibenclamide

Manju Gari, Rati Ranjan Debbarma, Lakhan Majhee, Subhankar Choudhury


Background: Diabetes is one of the largest global health emergencies of the 21st century and its co-existence with hypertension is frequent. These conditions often require polypharmacy with possible risk of drug interaction. This study is conducted to investigate the effect of amlodipine on blood glucose level in euglycemic and diabetic rats and its pharmacodynamic interaction with glibenclamide.

Methods: Rats were divided into six groups of 6 rats in each group. Group 1 and 3 were non-diabetic given 1% Gum acacia and amlodipine respectively. Group 2, 4, 5 and 6 were made diabetic by using nicotinamide and streptozotocin injection intra peritoneally and given 1% Gum acacia, glibenclamide, amlodipine and amlodipine + glibenclamide respectively for the period of 28 days. Fasting Blood Glucose (FBG) levels were measured before induction of diabetes, 72 hrs after the induction, on day 0, 7th, 14th, 21st and 28th day.

Results: Amlodipine produced no significant effect on FBG level in non-diabetic rats but in diabetic rats statistically significant hyperglycemia were observed on day 21st and 28th of study with the ‘p’ value (<0.05). Glibenclamide treated rats shows better controlled FBG level throughout study than concomitant administration of glibenclamide with amlodipine. Significant rise in blood FBG level with ‘P’ value (<0.05) were observed in amlodipine + glibenclamide treated group on 21st and 28th day of study.

Conclusions: This study suggest amlodipine produce no effect on the FBG level of normal rats but causes significant hyperglycemia in diabetic rats. Hypoglycemic effect of glibenclamide gets blunted when co-administered with amlodipine.


Amlodipine, Diabetes, Drug interactions, Glibenclamide

Full Text:



The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. Jan 2003,26(1):1183-97.

Melmed S, Polonsky KS, Reed Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 12th Ed. Philadelphia: Elsevier/Saunders; 2011:1371-1435.

Atlas ID. International Diabetes Federation, Brussels, 2015. Available from: [Last accessed: 2nd April, 2017]

Staessen JA, Birkenhäger WH, Fagard RH. Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients. 2000:2-7.

Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine. 2005 Dec 12;165(22):2644-50.

Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj. 2000 Aug 12;321(7258):412-9.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension. 2003 Dec 1;42(6):1206-52.

Makrilakis K, Bakris G. Diabetic hypertensive patients: improving their prognosis. Journal of cardiovascular pharmacology. 1998 Jan 1;31:S34-40.

Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes care. 2002 Jan 1;25(1):134-47.

Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA. 2000 Jun 28;283(24):3177-9.

May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic advances in endocrinology and metabolism. 2016 Apr 1;7(2):69-83.

Martindale. The complete drug references. 36th Ed. Vol.1, London: Pharmaceutical press; 2009:1342-1343.

Kaplan NM. Treatment of coexisting diabetes and hypertension. Current cardiology reports. 2001 Nov 1;3(6):498-503.

Kiienburg E, Schernthaner G. Metabolic Effects of Isradipine Versus Hydrochlorothiazide in Diabetes Mellitus. Hypertension. 1991;17(1):15-21.

Owolabi OJ, Omogbai EKI. Co-administration of Glibenclamide and Amlodipine Induces Resistance to Hyperglycemia Treatment in Streptozotocin induced Adapted/Non-adapted Diabetic rats; Clin Exp Pharmacol. 2011 Dec;1(1):102.

Wofford MR, King DS. Relationship between antihypertensive drugs and metabolic syndrome. Metabolic syndrome and related disorders. 2004 Sep 1;2(4):308-14.

Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998 Feb 1;47(2):224-9.

Ghosh MN. Some standard Techniques, In: Ghosh MN, editor, Fundamentals of Experimental Pharmacology, 5th Ed. Kolkata: Hilton and Company 2011:15-16.

Medhi B, Prakash A. Dose calculation for experimental animal, In: Practical Manual of experimental and clinical Pharmacology, 1st Ed. New Delhi: Jaypee Brothers Medical publishers; 2010:24.

Reddy BKK. A Study on Drug-Drug Interaction between Anti-Hypertensive Drug Combination Amlodipine and Telmisartan on Anti-Diabetic Effect of Glimepiride and Metformin in Normal and Streptozotocin Induced Diabetic Rats. JPBR. 2014;2(1):63-8.

Naidu SV, Suresha RN, Huralikuppi JC, Ashwini V, Satish AM, Brahadeesh M. Effect of Amlodipine on Oral Glucose induced Glycemic Changes in Normal Albino Rats. Int J Pharm Sci Res. 2012;3(9):3412-17.

Rani N, Sharma A, Singh R. Imidazoles as promising scaffolds for antibacterial activity: a review. Mini reviews in medicinal chemistry. 2013 Oct 1;13(12):1812-35.

Reddy KJ. Pharmacodynamic Interactions of Amlodipine and Enalapril with Glyburide in Normal and Diseased Rats. American Journal of Pharm Tech Research. 2016;6(2):504-29.

Bruton LL, Laso JS, Parker KL. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia, Goodman and Gilman’s, The Pharmacological basis of Therapeutics, 12th Ed. McGraw-Hill companies, 2011:1255-1257.